62055 20190819101354.0 doi 10.4321/S1130-01082013000100005 sideral 100050 ART-2013-100050 eng Ortiz-Lucas, M. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis 2013 Access copy available to the general public Unrestricted Background and objectives: immune system alteration in irritable bowel syndrome (IBS) patients may be modulated by probiotics. We assessed the efficacy of some probiotic species in alleviating characteristic IBS symptoms. Material and methods: a meta-analysis of all identified randomized controlled trials comparing probiotics with placebo in treating IBS symptoms was performed with continuous data summarized using standardized mean differences (SMDs) with 95% confidence intervals (95% CIs), where appropriate. The randomeffects model was employed in cases of heterogeneity; otherwise, fixed-effects models were used. Results: meta-analysis was performed with 10 of 24 studies identified as suitable for inclusion. Probiotics improved pain scores if they contained Bifidobacterium breve (SMD, -0.34; 95% CI, -0.66; -0.02), Bifidobacterium longum (SMD, -0.48; 95% CI, -0.91; -0.06), or Lactobacillus acidophilus (SMD, -0.31; 95% CI, -0.61; -0.01) species. Distension scores were improved by probiotics containing B. breve (SMD, -0.45; 95% CI, -0.77; -0.13), Bifidobacterium infantis, Lactobacillus casei, or Lactobacillus plantarum(SMD, -0.53; 95% CI, -1.00; -0.06) species. All probiotic species tested improved flatulence: B. breve (SMD, -0.42; 95% CI, -0.75; -0.10), B. infantis, L. casei, L. plantarum(SMD, -0.60; 95% CI, -1.07; -0.13), B. longum, L. acidophilus, Lactobacillus bulgaricus, and Streptococcus salivarius ssp. thermophilus (SMD, -0.61; 95% CI, -1.01; -0.21). There was not a clear positive effect of probiotics concerning the quality of life. Conclusions: some probiotics are an effective therapeutic option for IBS patients, and the effects on each IBS symptom are likely species-specific. Future studies must focus on the role of probiotics in modulating intestinal microbiota and the immune system while considering individual patient symptom profiles. info:eu-repo/semantics/openAccess by-nc http://creativecommons.org/licenses/by-nc/3.0/es/ 1.317 2013 GASTROENTEROLOGY & HEPATOLOGY 64 / 75 = 0.853 2013 Q4 T3 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Tobias, A. (orcid)0000-0002-7997-3619 Saz, P. Universidad de Zaragoza (orcid)0000-0003-1272-7365 Sebastián, J.J. Universidad de Zaragoza 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 105, 1 (2013), 19-36 Rev. esp. enferm. dig. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 1130-0108 266013 http://zaguan.unizar.es/record/62055/files/texto_completo.pdf Versión publicada 8583 http://zaguan.unizar.es/record/62055/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:62055 articulos driver 2019-08-19-09:51:58 ARTICLE